] i ) is generally considered the major event of the activation process of the contractile apparatus in smooth muscle cells. However, the kinetic, the pattern of the [Ca 2+ ] i increase, and its temporal correlation with the contractile response are not yet clearly understood. Techniques such as enzymatic isolation of smooth muscle cells and microspectrofluorimetry (using fluorescent indicators such as indo 1, fura 2, and fluo 3), allowing the measurement of the [Ca 2+ ] i in single cells, sometimes combined with electrophysiological experiments (patch clamp), are now widely used and have brought about new and important information in the field of cellular Ca 2+ signaling. Studies from our laboratory as well as from others have revealed that agonists controlling smooth muscle tone via activation of membrane receptors induce a complex temporal [Ca 2+ ] i response in single cells from some smooth muscles (e.g., vascular, airways, intestine). This response is composed of a series of cyclic increases in the [Ca 2+ ] i , so-called Ca 2+ oscillations. The pattern of these oscillations depends on several factors, including the type of tissue/species, the phenotype of the cells, e.g., fresh vs. cultured cells, and the agonist considered.
Characteristics of agonist-induced Ca 2+ oscillations
As a general feature, Ca 2+ oscillations are produced in single, freshly isolated smooth muscle cells in response to agonists interacting with seven transmembrane domain, G-coupled surface membrane receptors, such as acetylcholine (ACh), angiotensin II (AII), endothelin-1 (ET-1), extracellular ATP and UTP, noradrenaline, vasopressin, serotonin, and so forth. When agonists are applied by means of superfusion or microejection near the cell, the [Ca 2+ ] i rises, after a delay of 5-10 s, from a resting value of ~100 nM to a peak value of 400-800 nM (2, 11, 13) . This first increase is transient and followed by successive peaks of constant duration. The frequency varies from 4-6 to 25-30/min, according to the type of cell and/or the agonist concentration (see below). In some cases, the [Ca 2+ ] i returns to its resting value between each increase (2, 5, 11), whereas in others, [Ca 2+ ] i remains above its resting value between each increase (6) (Fig. 1, A and B) . These two patterns correspond to the so-called baseline spiking and sinusoidal types of oscillations, respectively. In these smooth muscles exhibiting Ca 2+ oscillations, the average percentage of oscillating cells is ~50-80% under identical experimental conditions. In contrast, we and others have consistently failed to observe oscillations in smooth muscles such as uterus, saphenous, and portal veins (Fig. 1, E and F ] i (see below). The concentration of agonist is the main factor that modulates the pattern of Ca 2+ oscillations in smooth muscle cells. However, this modulation depends on both the type of tissue and the agonist considered. In some cases (e.g., rat and porcine tracheal muscle, human uterine arteries, rat aorta, and so forth), the frequency, but not the amplitude, of oscillations increases with the concentration of agonist, the maximal frequency usually being observed in response to the same concentration as that producing the maximal mechanical response (6, 13) . In other cases (e.g., cultured cells from canine pulmonary arteries), both the amplitude and the frequency of Ca 2+ oscillations increase with the concentration (5) . Finally, in some other smooth muscles (e.g., rat pulmonary artery), the overall pattern of oscillations appears to be mainly independent of the agonist concentration, but the percentage of cells exhibiting Ca 2+ oscillations in response to agonist stimulation does depend on the agonist concentration (2, 6) . In this latter case, the combination of the number of responding cells with the amplitude of the first [Ca 2+ ] i peak also reveals a relationship between the concentration of agonist and the [Ca 2+ ] i response (6) . oscillations, is an intracellular store (mainly the sarcoplasmic reticulum) (Fig. 2) . Hence, agonist-induced Ca 2+ oscillations appear to be underlaid by a cytosolic Ca 2+ oscillator. Agonist-induced Ca 2+ oscillations are inhibited by 1) neomycin or U73122 (2, 5, 6) , potent inhibitors of the phosphoinositide phospholipase C (PI-PLC), and 2) phorbol ester (2, 6), specific activators of protein kinase C (PKC). These results indicate that the IP 3 pathway is implicated in the mechanism of Ca 2+ oscillations for the following reasons. On the one hand, agonists acting on G q/11 -coupled receptors such as AII and ET-1 increase both [Ca 2+ ] i and IP 3 concentration. On the other hand, direct activation of PKC by phorbol esters produces a negative feedback modulation of PI-PLC and thus a concomitant inhibition of agonist-stimulated IP 3 generation. Moreover, the delay (5-7 s) between the beginning of agonist ejection and the development of the first rise in [Ca 2+ ] i observed in smooth muscle cells (2, 6 ) is in agreement with the rapid rise (5-20 s) in IP 3 concentration produced by the same agonists in cultured arterial myocytes. This finding further supports the hypothesis that the IP 3 pathway is implicated in the mechanism of Ca 2+ oscillations. Finally, direct confirmation of this hypothesis has been obtained by introducing low-molecular weight heparin, a specific inhibitor of IP 3 ] i oscillations (3, 10) . Whereas the abovedescribed results undoubtedly indicate that the IP 3 pathway is implicated in the mechanism of Ca 2+ oscillations, the origin of the cyclic character of [Ca 2+ ] i variation requires further discussion since it could be due to either a cyclic discontinuous production of IP 3 (receptor-controlled oscillator) or a cyclic opening and closure of the RIP 3 (second messenger-controlled oscillator). So far, no direct evidence for a cyclic agonist-mediated production of IP 3 has been reported in smooth muscle. In contrast, the regulation of RIP 3 in smooth muscle is complex and involves positive and negative feedback controls by cytosolic and/or luminal Ca 2+ (7) . Ca 2+ acts as a cofactor at the site of RIP 3 from the cell and the sequestration of Ca 2+ into intracellular stores (Fig. 3) . There is the following additional evidence in favor of a main role of RIP 3 -release systems located at the sarcoplasmic reticulum membrane site. One is the RIP 3 underlying Ca 2+ oscillations through the IP 3 -induced Ca 2+ release (IICR) mechanism, the other is the ryanodine receptor/channel protein (RyR) responsible for the CICR mechanism, which is potentiated by caffeine (Fig. 3) .
Cellular mechanisms of agonist-induced
Since RIP 3 clearly appears to be a key structure involved in agonist-induced Ca 2+ oscillations, the lack of such oscillations in some smooth muscles, despite their ability to produce IP 3 -channel blockers but are maintained in the presence of TG. These latter oscillations are due to spontaneous variation of the membrane potential value and correspond to a membrane oscillator. Interestingly, it has been shown in the guinea pig ileal smooth muscle that the cholinergic agonist carbachol (CCh) activates one or the other of these oscillators, depending on its concentration. At a low concentration (0.2 µM), CCh evokes Ca 2+ oscillations that are dependent on extracellular Ca 2+ and associated with action potential discharge, whereas at a high concentration (2 µM), CCh evokes Ca 2+ oscillations related to Ca 2+ release from internal stores (9). 
Role of agonist-induced Ca 2+ oscillations
In smooth muscle, as in nonexcitable cells, the role of Ca 2+ oscillations has not yet been clearly elucidated. As discussed above, in many types of smooth muscle, the oscillation frequency is sensitive to the agonist concentration. It is thus suggested that oscillations may represent a digitalization of the Ca 2+ signal, allowing a frequency-dependent control of the cellular response. For example, in rat tracheal myocytes, the relationship between ACh concentration and Ca 2+ oscillation frequency is similar to that between ACh concentration and the amplitude of contractile response (Fig. 4A) (13) . Ca 2+ oscillations are also implicated in the control of the membrane potential through the activation of Ca 2+ -activated ionic currents (chloride, potassium, or nonspecific cationic currents) (1, 15) . For example, in swine tracheal and rat pulmonary arterial myocytes clamped at a value near the resting potential, agonists (ACh, AII, ET 1 , and ATP) induce an oscillatory inward current, the pattern of which is similar to that of Ca 2+ oscillations (Fig. 4B) (1, 3, 10, 15) . This current is mainly independent of extracellular Ca 2+ but disappears after treatment of cells with TG. Electrophysiological and pharmacological characteristics indicate that this oscillatory current is carried by Cl -ions (1, 3, 10) . Moreover, simultaneous measurement of membrane current (by means of the patch-clamp technique) and [Ca 2+ ] i in the same single smooth muscle cell has revealed that 1) each peak of inward current corresponds to a peak of [Ca 2+ ] i , 2) there is a relationship between the amplitude of each [Ca 2+ ] i peak and that of the corresponding membrane current, 3) heparin (added to the pipette solution) inhibits both the current and Ca 2+ oscillations, and 4) niflumic acid, which inhibits the current, has no effect on Ca 2+ oscillations (Fig. 4B ) (3, 6) . These data clearly demonstrate that oscillations in the ] i . Depending on the electrophysiological conditions, the resulting Ca 2+ -activated chloride current could participate in the membrane depolarization that secondarily opens voltagegated Ca 2+ channels, implicating the extracellular Ca 2+ source in the agonist-induced contractile response (Fig. 3) (3, 6, 10 
Conclusion
In a variety of smooth muscle cells, it has now been clearly demonstrated that agonists produce cytosolic Ca 2+ oscillations. In most of the cases, these oscillations are due to a cyclic release of Ca 2+ from intracellular stores through the RIP 3 , as a consequence of the dual effect of cytosolic Ca 2+ itself on the control of the channel. Although the understanding of the precise role of these oscillations requires further investigation, as a general rule oscillations may allow Ca 2+ to function as a messenger while obviating the deleterious effect of sustained elevation of [Ca 2+ ] i . Moreover, Ca 2+ oscillations can contribute to a frequency-dependent control of smooth muscle cell response and to the value of membrane potential via the control of Ca 2+ -dependent membrane ion channels.
There is also increasing evidence that pharmacological and/or pathophysiological factors modulate smooth muscle responsiveness via an alteration in Ca 2+ oscillations. Nitric oxide (NO) and NO donors, β-adrenoceptor agonists, intravenous anesthetics, or benzodiazepines reduce the frequency of Ca 2+ oscillations along with inducing relaxation, whereas gas pollutants do the opposite (14) . These results obtained mostly in vascular or airway smooth muscles suggest that Ca 2+ oscillations should be taken into account to better understand the pathophysiology and treatment of smooth muscle diseases such as hypertension, asthma, and remodeling of vascular or airway wall.
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